Insmed Inc (INSM)vsReviva Pharmaceuticals Holdings Inc. (RVPH)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RVPH
Reviva Pharmaceuticals Holdings Inc.
$0.83
+0.18%
HEALTHCARE · Cap: $11.37M
Smart Verdict
WallStSmart Research — data-driven comparison
RVPH leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RVPH
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RVPH
The strongest argument for RVPH centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RVPH
The primary concerns for RVPH are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RVPH is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
RVPH generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Reviva Pharmaceuticals Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical firm focused on developing innovative therapies to address central nervous system (CNS) disorders and other significant health challenges. Its lead candidate, RP5063, offers a novel therapeutic approach for treating schizophrenia and mood disorders, underscored by a proprietary drug delivery platform designed to enhance treatment efficacy. With a robust pipeline and a commitment to meeting critical unmet medical needs, Reviva is strategically positioned for growth in the evolving mental health market as it advances through key clinical development milestones.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?